41 results about "Diastolic heart failure" patented technology

Techniques are provided for predicting the onset of a heart condition within a patient based on impedance measurements. Briefly, overloads in fluid levels in the thorax and in ventricular myocardial mass within the patient are detected based on impedance signals sensed using implanted electrodes. The onset of certain heart conditions is then predicted based on the overloads. For example, pulmonary edema arising due to diastolic heart failure is predicted based on the detection of on-going overloads in both fluid levels and ventricular mass. Ventricular hypertrophy is detected based on an on-going ventricular mass overload without a sustained fluid overload. Various other heart conditions may also be predicted based on specific combinations of recent or on-going overloads. Evoked response is exploited to corroborate the predictions. Appropriate warning signals are generated and preemptive therapy is initiated.

A method and device featuring at least one component providing a potential to kinetic converted elastic, magnetic repulsion, or, an elastic and magnetic repulsion, pushing, pulling, or, pulling and pushing, type of radially outward expansive force or pressure to an inner, outer, intermediate, and, combination thereof, wall region of the left ventricle, for reducing intraluminal hydrostatic pressure of the left ventricle (LV filling pressure) during the ventricular diastolic stage of the cardiac cycle, thereby, improving diastolic function of the left ventricle of the heart in subjects having a condition of diastolic heart failure (DHF), while minimally disturbing systolic function of the heart. The expansive force or pressure is in a range of about 5-40 mm Hg, whereby, left ventricular end diastolic pressure (LVEDP) is reduced down to the normal range of about 6-12 mm Hg, during ventricular diastole of the heart.

An implantable cardiac device is used to measure one or more parameters relating to cardiac activity of a patient's heart, from which diastolic heart failure (“DHF”) may be monitored and / or detected. These parameters are used to calculate ventricular isovolumetric relaxation time or a related time value. Heart conditions possibly having an influence on the ventricular isovolumetric relaxation time, other than heart conditions due to reduced compliance, may be detected and used to prevent an incorrect calculation of the ventricular isovolumetric relaxation time. The parameters may be measured and the relaxation time calculated multiple times over a period of time, which enables monitoring of the progression of change in the relaxation time. The relaxation time and the progression of change therein are indicators of DHF.

An implantable medical apparatus for detecting diastolic heart failure, DHF, has a DHF determining device for determining at least one DHF parameter for detecting a DHF state of the heart of a patient. The DHF includes circuitry for determining, as the DHF parameter, the time duration of a predetermined phase of diastole. A pacemaker has such an apparatus and a control unit that optimizes pacing therapy and pacemaker settings depending on the determined time duration. A corresponding method of detecting diastolic heart failure, DHF, includes determining at least one DHF parameter for detecting a DHF state of the heart of a patient. As the DHF parameter, the time duration of a predetermined phase of diastole is determined.

Methods and systems for treating patients with diastolic heart failure (DHF) are disclosed which include slowing a patient's heart rate below its intrinsic rate, and controlling the rate using cardiac pacing therapy to improve LV filling and cardiac output. In certain embodiments, a pacing treatment rate may be determined by adjusting an adaptive rate by an amount determined by evaluating one or more patient parameters.

In an implantable medical device for detecting and / or monitoring the progression of diastolic heart failure (DHF), and a corresponding method, a parameter is measured that is indicative of left ventricular ejection fraction (LVEF), and a variable is also measured that is indicative of the workload of the patient, and a relation is determined between LVEF and the workload, and DHF is detected and / or the progression of DHF is monitored, dependent on this relation.

Techniques are provided for use with an implantable medical device for delivering left atrial (LA) pacing to address Diastolic Heart Failure, also referred to as Heart Failure with Preserved Ejection Fraction. In one example, pulse delivery times are selected for delivery of LA pacing pulses sufficient so that activation of the LA occurs when LA pressure (LAP) is lower than would occur in the absence of LA pacing. The pulse delivery times and also set so that subsequent activation of the right ventricle (RV) occurs when LAP is lower than would occur in the absence of LA pacing. LA pacing then is delivered by the implanted device at the selected pulse delivery times to mitigate Diastolic Heart Failure or to address other conditions.

Disclosed herein are methods of detecting or predicting diastolic heart failure in a subject, comprising identifying a profile of matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs) from a body fluid of the subject that is associated herein with the existence of likely development of left ventricular dilation (LVD).

The invention belongs to the field of medicine and particularly relates to an application of a pharmaceutical composition taking isosorbide mononitrate and ivabradine as active pharmaceutical ingredients in preparation of medicine for treating diastolic heart failure. By conformation through a lot of pharmacology experiment, the isosorbide mononitrate and the ivabradine can obviously improving heart diastolic function of patients with diastolic heart failure, and remarkable synergistic effect is achieved in the aspect of treating the diastolic heart failure. The pharmaceutical composition is obvious in treating effect and little in side effects in treating the diastolic heart failure, and is quite good in medical application prospect.

An implantable medical apparatus for detecting diastolic heart failure, DHF, has a DHF determining device for determining at least one blood pressure parameter for detecting a DHF state of the heart of a patient. The DHF determining device has a pressure measuring unit for measuring the absolute value of left atrial pressure during the diastasis phase just before atrial contraction, or the absolute value of the pressure in the pulmonary vein when the pulmonary valve is closed, for a predetermined workload situation and a rest situation of the patient. A comparator compares the difference between left atrial pressure or pulmonary vein pressure, in the workload and rest situations, with a predetermined pressure difference reference value. A pacemaker includes such an apparatus and a control unit that optimizes pacing therapy depending on the result of the comparisons with the reference values. In a corresponding method of detecting diastolic heart failure, DHF at least one blood pressure parameter for detecting a DHF state of the heart of a patient is determined. The absolute value of left atrial pressure is measured during the diastasis phase just before atrial contraction, or the absolute value of the pressure in the pulmonary vein when the pulmonary valve is closed, for a predetermined workload situation and a rest situation of the patient. The difference between left atrial pressure or pulmonary vein pressure in said workload and rest situations is compared with a predetermined pressure difference reference value.

The invention discloses a truncated growth differentiation factor 11 (GDF11) with biological activity and a preparation method thereof and belongs to the technical field of biological medicines. The truncated growth differentiation factor 11 comprises 95 amino acids, wherein the amino acid sequence is as shown in SEQ ID NO.1 The biological activity of the obtained truncated growth differentiation factor 11 is researched, and the result shows that the truncated GDF11 is capable of stimulating collagen secretion of fibroblasts and has the activity of promoting phosphorylation of cardiac fibroblasts Smad2 / 3 and activating a passage of the cardiac fibroblasts Smad2 / 3. Therefore, the truncated growth differentiation factor 11 has a wide application prospect in treatment or prevention of irreversible senile diseases such as a diastolic heart failure and alzheimer disease.

An implantable medical apparatus for detecting diastolic heart failure, DHF, has a DHF determining device for determining at least one DHF parameter for detecting a DHF state of the heart of a patient. The DHF includes circuitry for determining, as the DHF parameter, the time duration of a predetermined phase of diastole. A pacemaker has such an apparatus and a control unit that optimizes pacing therapy and pacemaker settings depending on the determined time duration. A corresponding method of detecting diastolic heart failure, DHF, includes determining at least one DHF parameter for detecting a DHF state of the heart of a patient. As the DHF parameter, the time duration of a predetermined phase of diastole is determined.

Disclosed herein are methods of detecting and predicting diastolic heart failure and predicting congestive heart failure comprise protease and protease inhibitor profiling.

The invention discloses a cardiotonic capsule for treating chronic heart failure and belongs to the field of traditional Chinese medicines. A preparation method of the cardiotonic capsule comprises the following steps of mixing 3-5 parts by mass of milkvetch root, 3-5 parts by mass of red ginseng, 3-5 parts by mass of prepared monkshood, 2-10 parts by mass of semen lepidii, 3-5 parts by mass of radix ophiopogonis, 2-3 parts by mass of Chinese magnoliavine fruit, 2-3 parts by mass of polygonatum odoratum, 3-5 parts by mass of radix salviae miltiorrhizae, 2-3 parts by mass of ligusticum wallichii, 3-5 parts by mass of kudzuvine root powder, 3-5 parts by mass of radix notoginseng and 3-5 parts by mass of leech, crushing the mixture into fine powder, and filling the fine powder into capsules. The cardiotonic capsule for treating chronic heart failure does not produce any toxic and side effect, is not limited by contraindication, has good effects of treating chronic constrictive and diastolic heart failure, is especially suitable for diastolic heart failure, can improve heart failure symptoms, can correct heart failure pathological and physiological changes, can reverse atherosclerosis, and can improve ischemic myocardial injuries, cardiac muscle and blood vessel remodeling and long-term prognosis of heart failure patients.

The invention discloses methods of detecting and predicting diastolic heart failure and predicting congestive heart failure comprising protease and protease inhibitor profiling.

The invention relates to a pharmaceutical composition for the treatment of cardiac fibrosis or heart diseases accompanied by cardiac fibrosis. According to the invention, the composition of the invention has an effect of dissolving a fibrosis matrix and performing restoration to normal tissues by selectively destroying myofibroblasts in cardiac fibrosis which is diagnosed after a disease occurs, and therefore can be usefully used as a composition for the treatment of cardiac fibrosis, systolic heart failure and diastolic heart failure for which a therapeutic agent has not been developed due tobeing considered as an irreversible disease progression up to date.

Methods and systems for treating patients with diastolic heart failure (DHF) are disclosed which include slowing a patient's heart rate below its intrinsic rate, and controlling the rate using cardiac pacing therapy to improve LV filling and cardiac output. In certain embodiments, a pacing treatment rate may be determined by adjusting an adaptive rate by an amount determined by evaluating one or more patient parameters.

In a method and implantable medical apparatus for detecting diastolic heart failure (DHF), and a pacemaker embodying such an apparatus, movement of the valve plane of the heart is measured and analyzed to identify a slowing of the movement of the valve plane as an indication of a DHF state of the heart. A signal indicative of this DHF state is emitted and, in the pacemaker, is used to control the administration of a pacing pulse therapy to the heart.

A method for the treatment or prevention of cardiac hypertrophy or diastolic heart failure resulting from cardiac hypertrophy by administering levosimendan or its metabolite (II) or any of their pharmaceutically acceptable salts to a mammal in need of such treatment.

The present invention relates to a pharmaceutical composition for the treatment of cardiac fibrosis or heart diseases accompanied by cardiac fibrosis. According to the present invention, the composition of the present invention has an effect of dissolving a fibrosis matrix and performing restoration to normal tissues by selectively destroying myofibroblasts in cardiac fibrosis which is diagnosed after a disease occurs, and therefore can be usefully used as a composition for the treatment of cardiac fibrosis, systolic heart failure and diastolic heart failure for which a therapeutic agent has not been developed due to being considered as an irreversible disease progression up to date.

The invention relates to a system and method for establishing a mouse model of diastolic heart failure (DHF) and cardiac resynchronization therapy (CRT), and belongs to the technical field of cardiovascular disease animal models. The system comprises a pace-making system and an electrocardiograph (ECG) record system, wherein one end of a pace-making lead of the pace-making system is connected withmyocardium of a mouse, and the other end of the pace-making lead is connected with a pulse generator through a row needle terminal; and one end of an ECG lead of the ECG record system is connected with pectoralis major muscle of the mouse, and the other end of the ECG lead is connected with an ECG through a row needle terminal. The system can quickly realize heart pace-making through the exogenous pulse generator and the metal pace-making lead to realize DHF and CRT and is connected with the heart and the exogenous pulse generator through the metal ECG lead to record ECG activity. The established mouse model of the DHF and CRT can be applied to basic research about the DHF and CRT later. The system is simple in composition and structure, convenient to produce and lower in manufacturing cost.

The invention discloses application of a mitochondrial fission factor (MFF) to a heart failure, and particularly relates to application of the MFF to preparation of drugs for treating and detecting heart failure diseases. Provided data show that in a plurality of diastolic heart failure rats, the change (rise) of the MFF expression quantity is positively correlated with the diastolic heart failure, MFF protein causes apoptosis by promoting mitochondrial fission, the MFF can further be applied to clinical detection of the diastolic heart failure, meanwhile, the MFF can further be applied to development of the heart failure drugs, and a new method and scheme are provided for treatment of the diastolic heart failure.

The invention relates to a functional artificial system for a left ventricle and belongs to the field of biomedical engineering. The system is composed of a drive and control system, a sensor connecting line, a sensor, a driving shaft, a blood storage chamber, a hemispherical piston and an elastic seal film. The system is applied to treatment and assistance of a diastolic heart failure sufferer; and a system main body is fixed to a cardiac apex position, penetrates through cardiac muscles and extends into the left ventricle, the elastic seal film is used for blocking off blood, the sensor is used for acquiring electrocardiosignals of the sufferer, the signals are transmitted to the drive and control system through the sensor connecting line, and the drive and control system is used for carrying out analysis processing on the electrocardiosignals, then, controlling the driving shaft to rotate, then driving the hemispherical piston to rotate, and thus, controlling the internal volume ofthe blood storage chamber and the contraction and dilatation of a heart of the sufferer to synchronously change. The blood storage of the left ventricle can be increased at diastole, and the volume ejection of the ventricle can be increased at systole.

Disclosed herein are methods of detecting or predicting diastolic heart failure in a subject, comprising identifying a profile of matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs) from a body fluid of the subject that is associated herein with the existence of likely development of left ventricular dilation (LVD).

The present invention relates generally to the field of cardiac, vascular system, and heart assistance devices. It provides the energy required to keep the blood flowing in the pulmonary and systemic circuits to a desired level, acting on one or more chambers. Actual problems of Total Artificial Heart pumping blood are design limitations, infection, hemorrhage, end organ failure, thromboembolism, device disfunction, life span of diaphragms, and impossibility to restore the heart but with a transplant. The device is external and has four units replicating the natural heart and its dynamics, driving by a pneumatic transcutaneous system to provide the energy needed up to the desired working level of a healthy organ. Applications are on those types of surgical or clinical treatment of patients with Diastolic Heart Failure or used to treat Heart Failure with Reduced Ejection Fraction (Systolic Heart Failure), the device can be left connected permanently of for healing.

A method of treating diastolic heart failure includes implanting a cardiac implant in a heart of a subject diagnosed as suffering from diastolic heart failure. A superior portion of a flexible tether of the cardiac implant is anchored to one or more left-atrial sites of one or more walls of the left atrium. An inferior portion of the flexible tether is anchored to a site of a wall of a mid third of the left ventricle, of a wall of an apical third of the left ventricle, and / or of a papillary muscle of the left ventricle. As a result, the flexible tether reduces a volume of the left atrium during at least a portion of ventricular diastole of each cardiac cycle, thereby enhancing ventricular filling. Other embodiments are also described.